Clinical Trials Logo

Clinical Trial Summary

Prospective, observational study to explore the significance of gut microbiome in the diagnosis of ITP, and to identify the predictive value of baseline gut microbiome for GC resistance/relapse.


Clinical Trial Description

A prospective, observational study to (1) collect fecal samples from ITP patients at initial diagnosis (baseline) and after first-line GC treatment, (2) detect the composition of gut microbiome and related metabolites using metagenomic sequencing combined with metabolomics, (3) observe the impact of first-line treatment on gut microbiome, (4) explore the significance of gut microbiome in the diagnosis of ITP, and (5) identify the predictive value of baseline gut microbiome for GC resistance/relapse, thus to provide new ideas for clinical diagnosis and treatment of ITP. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05118126
Study type Observational
Source Peking University People's Hospital
Contact Xiao-Hui Zhang, Dr.
Phone +8613522338836
Email [email protected]
Status Not yet recruiting
Phase
Start date November 2021
Completion date December 2022

See also
  Status Clinical Trial Phase
Completed NCT02914054 - Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone Phase 2/Phase 3
Not yet recruiting NCT04943042 - An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
Recruiting NCT05116423 - Prediction Model for Critical ITP Bleeds in Primary Immune Thrombocytopenia Inpatients
Recruiting NCT04904276 - Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
Recruiting NCT04747080 - The Combination of Tacrolimus and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia Phase 2
Not yet recruiting NCT04482777 - IL37,Tlymphocytes,NK Cells in Pathogenesis of ITP
Recruiting NCT04703621 - The DART Study- Daratumumab Treatment in ITP Phase 2
Completed NCT04089267 - Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP) Phase 4
Not yet recruiting NCT04735588 - Investigation on the Incidence and Course of COVID-19 in Patients With Prior, Ongoing or de Novo ITP. Evaluation of the Impact of COVID-19 Pandemic on the Management of ITP